Agoracom Blog

Datametrex $DM.ca Awarded $217,000 by Department of National Defence for Completion of Phase 2 of Innovation Program

Posted by AGORACOM-JC at 8:50 AM on Wednesday, April 22nd, 2020
  • Department of National Defence approved the Company’s completion of the second phase of a multi-phase R&D program through the Department of National Defence’s Innovation for Defence Excellence and Security (IDEaS) program
  • Datametrex will be receiving approximately $217,000 CAD as payment for completion of phase 2
  • Company will continue to work on phase 3 of the program to further develop Nexalogy SMART, Social Media Automated Reporting Technologies

TORONTO, April 22, 2020 — Datametrex AI Limited (the “Company” or “Datametrex”) (TSXV: DM, FSE: D4G, OTC: DTMXF) is pleased to announce that the Department of National Defence approved the Company’s completion of the second phase of a multi-phase R&D program through the Department of National Defence’s Innovation for Defence Excellence and Security (IDEaS) program. Datametrex will be receiving approximately $217,000 CAD as payment for completion of phase 2.  The Company will continue to work on phase 3 of the program to further develop Nexalogy SMART, Social Media Automated Reporting Technologies. Due to confidentiality requirements, the Company is not permitted to provide additional details about the nature of the work being performed for the Department of National Defence.

IDEaS supports the development of solutions from their conceptual stage, through prototype testing and capability development. The program includes several elements that promote collaboration between innovators, provides developmental resources and provides opportunities to interact with DND’s science and military members. Through which all innovators are on an even playing field to solve specific defence and security challenges. For more info about the program, see here: https://www.canada.ca/en/department-national-defence/programs/defence-ideas.html

“The completion of phase 2, marks the halfway point of this project and reflects the important work we are doing to help the Government of Canada maintain a technological advantage in the realm of cyber social media security. We are happy to have the go ahead to continue the contract.” says Marshall Gunter, CEO of the Company.

For more information on this project or to learn how Datametrex can assist your organization in social media discovery or cyber security please go to: www.nexalogy.com

About Datametrex

Datametrex AI Limited is a technology focused company with exposure to Artificial Intelligence and Machine Learning through its wholly owned subsidiary, Nexalogy (www.nexalogy.com).

For more information about the IDEaS program please visit: Canada.ca/defence-ideas

For further information, please contact:

Marshall Gunter – CEO
Phone: (514) 295-2300
Email: [email protected]

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws.  All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

Mota Ventures $MOTA.ca Raises $2.8 Million in Additional Private Placement $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 8:03 AM on Wednesday, April 22nd, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564664/hub/MOTA_Large.png

VANCOUVER, BC / ACCESSWIRE / April 22, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTCPINK:PEMTF) (the “Company“) is pleased to announce that it has completed a further offering (the “Offering“) of 9,944,000 units (each, a “Unit“) by way of non-brokered private placement at a price of $0.28 per Unit for gross proceeds of $2,784,320. Each Unit consists of one common share of the Company, and one common share purchase warrant (each, a “Warrant“) exercisable to acquire an additional share at a price of $0.38 for a period of twenty-four months, expiring on April 21, 2022. When combined with the earlier offering completed by the Company on April 1, 2020, the Company has raised gross proceeds of $4,504,320.

The Company anticipates utilizing the proceeds of the Offering to further develop and market products in North America and Europe using its ecommerce sales channels, to satisfy compensation obligations owing to employees based on services provided to the Company and the satisfaction of performance metrics and for general working capital purposes. In connection with completion of the Offering, the Company has paid $75,120 and issued 262,857 common shares and 268,287 Warrants to certain arms-length parties who assisted in facilitating the Offering. The Company has also issued 142,857 Warrants to an arms-length consultant, as partial consideration for services provided to the Company.

All securities issued in connection with the Offering are subject to a four-month-and-one-day statutory hold period in accordance with applicable securities law.

About Mota Ventures Corp.

Mota Ventures is seeking to become a vertically integrated global CBD brand. Its plan is to cultivate and extract CBD into high-quality value-added products from its Latin American operations and distribute it both domestically and internationally. Its existing operations in Colombia consist of a 2.5-hectare site that has optimal year-round growing conditions and access to all necessary infrastructure. Mota is looking to establish sales channels and a distribution network internationally through the acquisition of the Sativida and First Class CBD brands. Low cost production, coupled with international, direct to customer sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS
MOTA VENTURES CORP.

Joel Shacker
President

For further information, readers are encouraged to contact Joel Shacker, President, at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Empower Clinics $CBDT.ca Continues to Advance Development of #Psilocybin and Psychedelics Division to Address Significant Mental Health Issues $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 7:20 AM on Wednesday, April 22nd, 2020

Empower is utilizing clinics, physicians, technology and direct access to 165,000 patients to launch dedicated division and resources for psilocybin research.

  • Created a subsidiary company dedicated to the advancement of psilocybin research and patient care, addressing the significant mental health issues of anxiety, depression, post-traumatic stress disorder and addiction
  • “Mental health conditions such as anxiety, depression, addiction and PTSD appear to be on the rise with the onset of the Coronavirus pandemic.” said Steven McAuley, Chairman & CEO of Empower

VANCOUVER, BC / April 22, 2020 / EMPOWER CLINICS INC. (CSE: CBDT)(OTC: EPWCF)(Frankfurt 8EC) (“Empower” or the “Company”), a vertically integrated and growth-oriented life sciences company is pleased to announce, it is has created a subsidiary company dedicated to the advancement of psilocybin research and patient care, addressing the significant mental health issues of anxiety, depression, post-traumatic stress disorder (PTSD) and addiction.

The Company is leveraging its assets that include the existing clinic network, the developing franchise brand, tele-medicine, access to its 165,000 patients and large physician team, to make advancements in psilocybin research and psychedelics therapy in general.

“Mental health conditions such as anxiety, depression, addiction and PTSD appear to be on the rise with the onset of the Coronavirus pandemic.” said Steven McAuley, Chairman & CEO of Empower. “Clinical trials continue to show that psilocybin therapies may provide tremendous help with these conditions, that we see every day in our clinics. As a Company, we must endeavour to utilize our assets and capabilities to positively impact patients’ lives.”

The mental health crisis could cost the world $16 trillion by 2030 according to Future Market Insights and further, the global behavioral health (non-pharmacological) market is expected to be valued at US$156 billion by 2028.

According to the World Health Organization (WHO), depression is the leading cause of disability worldwide, and it is a major contributor to the overall global burden of disease.

The United States Food and Drug Administration has determined that preliminary clinical evidence indicates psilocybin may demonstrate substantial improvement over other available therapies for treatment-resistant depression; and granted a Breakthrough Therapy designation for a treatment that uses psilocybin as a therapy for such depression.

ABOUT EMPOWER

Empower is a vertically integrated health & wellness brand with a network of corporate and franchised health & wellness clinics in the U.S. The Company is building its first hemp-derived CBD extraction facility and produces its proprietary line of cannabidiol (CBD) based products. The company is a leading multi-state operator of a network of physician-staffed wellness clinics, focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has commenced activity on how to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Steven McAuley

CEO

[email protected]

604-789-2146

Investors: Dustin Klein

SVP, Business Development

[email protected]

720-352-1398

For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding; the Company’s intention to create psilocybin and psychedelics divisions, that market research on advancements in psilocybin and psychedelics in North America and globally will create greater shareholder value, the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Psychedelic substances remain illegal in most countries, so please reference your local laws in relation to medical or recreational use. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

VIDEO: Datametrex $DM.ca Discusses Obtaining Rights to Import and Sell #COVID19 Test Kits From South Korea

Posted by AGORACOM-JC at 4:29 PM on Tuesday, April 21st, 2020

When US Government Agencies call you in the middle of the greatest health and economic crisis in 100 years to help them detect social media disinformation about COVID-19, it is safe to assume your Artificial Intelligence capabilities to detect fake news, disinformation campaigns and their impact is amongst the most respected in the world.  

But when the Canadian government calls on you to help with the import and sale of COVID-19 test kits from South Korea, it is also safe to assume your trust and security clearances are at the highest levels possible.    

You would probably also assume such a company to be a tech giant or a Silicon Valley funded startup.  But Datametrex AI (DM: TSXV) is neither.  Rather, it is a great Canadian small cap technology company who happens to have:  

“developed strong relationships with many large multi-national companies in South Korea.  As a result of these relationships, the Canadian Embassy in Seoul contacted Datametrex to ask for help in procuring rapid test kits.”

  If that wasn’t enough, Datametrex has also achieved the following as of late:

  • Q3 Revenues Of $1.6 million,  an increase of 186%
  • 9 Month Revenues Of $2.56M an increase of 37%
  • Repeat Contracts Of $1M and $600,000 With Korean Giant LOTTE   
  • $954,000 Contract With Canadian Department of Defence To Fight Social Media Election Meddling
  • Participation In NATO Research Task Group On Social Media Threat Detection 
  • Becoming an affiliate member of the Carnegie Mellon University Center for IDeaS

When a small cap Artificial Intelligence company is successfully deploying its technology with military and conglomerates, as well as, being called upon by the Canadian federal government to ask for help with the greatest pandemic in 100 years, smart small cap investors are compelled to take a closer look.  

That look can begin with our latest interview of Datametrex CEO, Marshall Gunter, who discusses obtaining the rights to import and sell COVID-19 test kits from South Korea and the impact it will have on the Company.  

Watch this interview on one of your favourite screens or hit play and listen to the audio as you drive. 

CLIENT FEATURE: Tartisan Nickel $TN.ca Kenbridge Property Hosts M&I Resource of 7.14 Million Tonnes of 0.62% Nickel + 0.33% Copper – $ROX.ca $FF.ca $EDG.ca $AGL.ca $ANZ.ca

Posted by AGORACOM-JC at 2:05 PM on Tuesday, April 21st, 2020
Tc logo in black

Investment Highlights

  • Kenbridge property has a measured and indicated resource of 7.14 million tonnes at 0.62% nickel, 0.33% copper
  • 17.5 (21.8 fully diluted) percent equity stake in Eloro Resources and 2 percent NSR in their La Victoria property

Kenbridge Ni Project (ON, Canada)

  • Advanced  stage  deposit  remains open  in  three  directions,  is  equipped with a 623m  deep  shaft  and  has  never  been  mined
  • Preliminary  Economic Assessment completed and updated returned robust project 
    economics and operating costs including  a  NPV  of  C$253M  and  cash costs of US$3.47/lb of nickel net of  copper credits
  • Plans for Kenbridge include updating PEA, advancing the project through to feasibility and exploring the open mineralization at depth

Recent News

  • Company has completed a Spectral Analysis Survey
  • Survey covered the patented and single-cell mining claims that make up the historic land position which contains the Kenbridge Deposit and the surrounding area, identifying several new exploration targets not only for nickel, copper, cobalt, but also for potential gold occurrences
  • Analysis Survey shows the distribution and intensity of up to 304 minerals, with the first pass showing up to 16 minerals
  • Each mineral can be classified into an exploration relevance for base metals, precious metals and industrial metals

Tartisan CEO Mark Appleby said, “the survey picked out the Kenbridge Deposit, and has shown the possible extension to the Kenbridge Deposit and three additional trends that relate directly to underlying geology and structure implicit in the Kenbridge Deposit. Of significant interest, the survey found two gold trends as well, which include the Violet and Nina historic gold occurrences. One of the occurrences is almost 54 hectares in size and covers almost all of three of our staked claims on the border of the Kenbridge property.”

Industry News

INDUSTRY BULLETIN: Nickel prices jump after Vale trims output target

INDUSTRY BULLETIN: Nickel prices get a boost from pandemic-driven ore supply tightness

INDUSTRY BULLETIN: Have the next crop of battery metals producers been oversold?

INDUSTRY BULLETIN: The thematic case for nickel

Click Here to View Kenbridge 43-101 Technical Report

FULL DISCLOSURE: Tartisan Nickel Corp. is an advertising client of AGORA Internet Relations Corp.

MUST WATCH: KABN Systems North America Online “Ask Me Anything” Event

Posted by AGORACOM-JC at 12:28 PM on Tuesday, April 21st, 2020

KABN Systems North America is in the business of verifying, managing and monetizing online Digital Identity.

Digital Data is the new “Gold”!

KABN North America empowers users to verify, protect, manage and profit from their Digital Identity.  With the recent changes to working, shopping, educating and playing from home, online usage and engagement is growing.

KABN’s business is:

  • About providing consumers with no-cost tools to manage their Digital Identity and profit from the public data.
  • Focused online making us Covid-19 resistant.
  • Relevant to 100% of the online, digital market.
  • Optimized for commercial partnerships in Financial Services, eCommerce, Education, Government, Healthcare, Technology, Gaming & more.
  • Built, scalable, proven and in market today.
  • Aligned with online revenue trends.
  • Run by a veteran team of successful industry leaders.
  • In process of a proposed RTO transaction for public listing.

CBD In Medicine: Relief and Regulation SPONSOR: Mota Ventures $MOTA.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 11:40 AM on Tuesday, April 21st, 2020
  • Neuropharmacologist and Functional Medicine practitioner Dr Elisabeth Philipps tells MCN about the therapeutic benefits of CBD and talks about CBD regulation.

MCN speaks to Dr Philipps about the science behind the health benefits of CBD and the need for standardised regulation of CBD food supplements.

Dr Elisabeth Philipps is a neuropharmacologist and practitioner in Functional Medicine with over 18 years’ experience. She operates a thriving health consultancy in the UK specialising in CBD, brain and gut health; where she provides expert opinion for private clients, corporate business programmes, the national media, specialist healthcare publications and health companies.

How did you first become aware of the endocannabinoid system and the therapeutic benefits of cannabis?

I’m a neuropharmacologist by training, so I’ve been aware of the medicinal therapeutic benefits of cannabis for a number of years. The endocannabinoid system was only discovered in the 1990s so it’s actually a relatively recent system that we’ve known about in the body, but it’s only been in the last two to three years that my focus has become much more intense on the endocannabinoid system, medicinal cannabis and CBD oil supplements; because of the rise in profile of those products.

What are the potential dietary benefits of consuming CBD or hemp?

The two products are quite different: hemp is extract of the whole plant, so the dietary benefits of hemp normally come from the hemp seed – you could have the seeds ground or sprinkled on top of your food, for example; maybe hemp seed oil which makes a good salad dressing. Hemp oil extracts are rich in very beneficial omega-3 and omega-6 essential fatty acids; you also find things like protein and fibre as well as minerals and vitamins: magnesium and phosphorus, for example, are found within the hemp seeds themselves.

CBD is an even more refined extract from the hemp plant flowers rather than the seeds, so there’s not so much [in the way of] dietary benefit; but it contains the compounds such as the phytocannabinoids, and other compounds such as flavonoids and terpenes, which can confer health benefits; so you get the dietary benefits from hemp seeds and hemp seed oil and you get other health benefits from consuming CBD.

What kind of conditions and ailments do you find that people are using CBD for?

[There are] three primary areas that people find CBD works for them: the sleep area, to help improve the quality of sleep; people report being able to [get to] sleep more easily, stay asleep and feel more refreshed when they wake up. [The second area is] pain, which comes in many different forms – it can be nerve pain or neurogenic pain or inflammatory pain, so conditions such as arthritis, for example, or more acute conditions such as sporting injuries or general inflammatory injuries. People report taking CBD oil as helping to reduce the response to pain. What’s been very interesting in the study of CBD and phytocannabinoids in pain pathways is that not only is it blocking the pain pathways themselves in the spinal cord and brain, but also CBD acts within the parts of the brain that helps change our perception of pain. That’s really key, because it’s how we respond to the pain signals in our bodies that gives us the intensity of the experience; so CBD is an important component of a programme to help manage different types of pain.

The third area that I find CBD can really help is in mood, in particular [for patients who are] feeling anxious or stressed. CBD has this ability, through various pathways in the brain, to help balance the systems that help us feel better, to improve wellbeing, to improve our mood. CBD works at the neurotransmitter level, transmitting chemicals in the brain that send signals to help provide a balance. There are a number of studies coming in: they’re relatively small scale, but they’re looking at CBD oil for anxiety and for sleep and they have showed improvement in those areas; but the science is beginning to play catch-up now as well.

What is the science behind the effects of CBD on different symptoms?

CBD interacts with our own endocannabinoid system and I think that’s really key, because when you take a medicine it’s a very blunt tool: it either turns something on or turns something off; it blocks a response or it produces a response. CBD is lot more subtle than that within the body, because it works within the endocannabinoid system and that system is spread throughout our body – the endocannabinoid system is in the gut, the brain, in the immune cells, in the lungs, in the skin – so that’s why CBD can have such a diverse number of effects.

We produce our own cannabinoids within the body to stimulate and produce effects; and CBD helps balance the body’s production and the body’s ability to activate the endocannabinoid system through its own naturally produced mediators. There’s a lot of science showing how CBD acts within the endocannabinoid system and produces its responses.

What advice do you have for consumers when choosing a brand or product to ensure it is good quality and does not contain any unlisted ingredients?

This can be a very confusing area, because there are so many products that have hit the market. First of all, a CBD food supplement is legal in the UK if it contains less than 0.2% THC or tetrahydrocannabinol. That is the cannabinoid which causes the commonly associated high or buzz that you get from marijuana; it’s only present in hemp in very low levels anyway and it’s been stripped out of CBD oil. You need to ensure that you’re taking a legal product that contains less than 0.2% THC; and you can do that by asking the company for a certificate of analysis.

Every batch of CBD oil that a reputable company receives will have had a third-party laboratory testing [conducted] on that particular batch of oil, which will have a batch number so it can all be traced. That will show the breakdown of the different cannabinoids and the different constituents of that particular oil so you’ll be able to see not only that it contains the legal limit or less of THC, but the amount of CBD that it says on the label as well – that’s where the product can vary drastically, so you need to have a look at that certificate of analysis to show that it contains the CBD that you want. You will find some companies selling 0% THC products, which are very useful especially if you are drug tested for work or if you’re a professional athlete. The Banned Substances Control Group (BSCG) can test for THC and other banned substances and can provide a certificate to show that you don’t have any of those substances within your product. Reputable companies should have their certificates of analysis on their websites; or have a chat with them and they should provide that information for you.

How do you anticipate the market will evolve in over the next few years?

This is a very interesting time for CBD and medical cannabis: there’s obviously a lot going on and there’s a lot in the news. I think there needs to be more CBD regulation within the industry, because there’s a wide range of products on the market that differ in terms of their CBD content and what they purport to have in them; so there needs to be more CBD regulation, there’s no doubt about that. Equally [there is a question of] how that CBD regulation is brought in: the industry is playing catch-up in a way because the popularity of the product has grown exponentially in the last few years.

What we need to see is regulation, working with food standards agencies and [other regulators] at a government level. I think that will evolve over the next few months and years; and it’s going to be [because of] FourFive and other reputable companies that are working with the regulators, to help the industry in a way that protects it and still provides consumers with quality products.

Working on the assumption that further CBD regulation is likely to be introduced, do you expect this to impact patients using these products?

There is no doubt that the CBD regulation will change; and that it needs to protect the industry in terms of protection of products and protect consumers as well. I think it’s a case of companies and experts working with both agencies and the regulators: the impact on patients is our primary concern; and we are working towards avoiding any impact so there is seamless availability of quality products on the market. That is a goal that everyone is working to at the moment: every country is different and we’re just going to have to keep working together to make sure that high quality products [are going] to be readily available.

Do you anticipate Brexit having an impact, either positive or negative, on CBD regulation and medicinal cannabis regulation?

Brexit will potentially free up time and space for this topic to be higher up agendas. I believe that Brexit has possibly moved discussions of CBD and medical cannabis off the table or further down the list [of priorities]. I do think we’ll see more discussions happening in the next few weeks and months as Brexit resolves. At the moment we’re still working under European guidelines, in terms of the food supplement side at least, but it will be interesting to see how that pans out as we leave Europe; and as with many different areas of Brexit it’s still a bit of an unknown as to how EFTA’s [the European Free Trade Association] regulations and rules will affect the Food Standards Agency on the UK side. There will definitely be more discussion around this, certainly in the groups that I’m involved with; and we know that there are greater discussions to be had in the next few months.

Dr Elisabeth Philipps
Nutritional Therapist
www.hartwellnutrition.co.uk

SOURCE: https://www.healtheuropa.eu/cbd-in-medicine-relief-and-regulation/99418/

PyroGenesis $PYR.ca Receives Additional $457K Under Exclusive Agreement with US Tunneling Company $RTN $NOC $UTX $HPQ.ca $DDD.ca $SSYS $PRLB

Posted by AGORACOM-JC at 11:09 AM on Tuesday, April 21st, 2020
  • Announced today that, further to its press release dated April 1st, 2020, it has received an additional US$325K (approx. CA $457K) under the exclusive agreement with a US based tunneling company
  • To date, the Company has received US $725K (over CA $1M) in total

MONTREAL, April 21, 2020  — PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX-V: PYR) (OTCQB: PYRNF) (FRA: 8PY), a high-tech company, (the “Company”, the “Corporation” or “PyroGenesis”) that designs, develops, manufactures and commercializes plasma atomized metal powder, plasma waste-to-energy systems and plasma torch systems, is pleased to announce today that, further to its press release dated April 1st, 2020, it has received an additional US$325K (approx. CA $457K) under the exclusive agreement (the “Agreement”) with a US based tunneling company (the “Client”). To date, the Company has received US $725K (over CA $1M) in total. The Client’s name will remain anonymous for confidentiality and competitive reasons.

“This is an ideal contract, given the current situation, where all the engineering work can be done remotely,” said Mr. Peter Pascali, CEO of PyroGenesis Canada Inc. “This relationship is timely, given the current environment where investors are more focused on multiple secure revenue streams.  It is important to note that this relationship was not born out of the current crisis and, as such, is expected to continue well after the pandemic is behind us.”

Under this Agreement, PyroGenesis will not only develop and supply high-powered plasma torches, specifically designed for tunneling applications, but will also be intimately involved in all aspects of design and development for the entire project. Upon success, the Client is committed to purchase exclusively, and PyroGenesis is committed to exclusively supplying, plasma torches and auxiliary equipment for these applications. The scope of work is now comprised of several phases, each being defined by the results from the former.

PyroGenesis’ high-powered plasma torch will be used to replace traditional tunneling methods. An important benefit in using plasma-based tools versus traditional methods, is its potential to drill through all geologies with greater flexibility in size diameter, while at the same time being more economical, efficient and environmentally friendly.

“Once again, this Agreement underscores our plasma torch expertise, and we are pleased to be applying it to a very unique and significant opportunity,” said Mr. Alex Pascali, Business Development Manager of PyroGenesis. “This highlights the fact that we not only sell plasma torches, but also provide the expertise required to develop cutting edge plasma-based applications. The Company continues to increase revenues and reduce risk by diversifying its customer base with a standard product offering.  This is just one of many exciting developments at PyroGenesis these days.”

About PyroGenesis Canada Inc.

PyroGenesis Canada Inc., a high-tech company, is the world leader in the design, development, manufacture and commercialization of advanced plasma processes and products. We provide engineering and manufacturing expertise, cutting-edge contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, advanced materials (including 3D printing), oil & gas, and environmental industries. With a team of experienced engineers, scientists and technicians working out of our Montreal office and our 3,800 m2 manufacturing facility, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. Our core competencies allow PyroGenesis to lead the way in providing innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. Our operations are ISO 9001:2015 and AS9100D certified, and have been since 1997. PyroGenesis is a publicly-traded Canadian Corporation on the TSX Venture Exchange (Ticker Symbol: PYR) and on the OTCQB Marketplace. For more information, please visit www.pyrogenesis.com.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward- looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Corporation’s current expectation and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Corporation with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Corporation’s ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com, or at www.otcmarkets.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Corporation undertakes no obligation to publicly update or revise any forward- looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws. Neither the TSX Venture Exchange, its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the OTCQB accepts responsibility for the adequacy or accuracy of this press release.

SOURCE PyroGenesis Canada Inc.

For further information please contact:
Rodayna Kafal, Vice President Investors Relations and Strategic Business Development
Phone: (514) 937-0002, E-mail: [email protected]
RELATED LINK: http://www.pyrogenesis.com/

The Gold / Silver Ratio: It Will Keep On Climbing SPONSOR: Affinity Metals $AAF.ca $SII.ca $TUD.ca $GTT.ca $AMK.ca $OSK.ca $RKR.ca

Posted by AGORACOM at 10:31 AM on Tuesday, April 21st, 2020

The gold silver ratio has been rising for nine years.

There are many commentators suggesting that the gold silver ratio is nearing a top at present. Here and here are good examples. I am not of that opinion and consider that it will keep climbing for the next 10 years at least. Below is a chart of the gold silver ratio (Source)

As you can see, the chart shows that the gold silver ratio hit a high of 125.89 on the 18th March 2020 and has since declined back to 111.81 (16/4/20). It is likely over time to retest and break the recent highs and then keep on climbing.

The analysis

To understand why the ratio is going to keep on climbing, we need to look at how gold and silver are used.

Silver

Below is the breakdown of the percentage usage of silver in the US:

Source

As you can see, 45% is used in photography and electrics. The other category (24%) is a mix of energy use, brazing and soldering, chemical production, mirror production and medicine (see link above). In total therefore 69% is used in industry. Only 31% is used in jewelry and coins (silver kept in circulation).

Gold

Below is a breakdown of the percentage uses of gold in the US:

Source

Industrial use of gold is only 37%, but 58% is used in coins and jewelry (gold kept in circulation).

Conclusion

As silver is 69% used in industry and gold only 35%, silver is much more sensitive to the strength of the economy than gold is. The last economic cycle in the US was the weakest in modern economic history. Real potential GDP was 1.6% from 2008 to 2018 (Source). This is the lowest 10-year rate since before the Second World War. The gold silver ratio is therefore doing exactly what you would expect it to do in a weak economic backdrop. It is steadily rising. If the economy remains weak after the present recession, I would expect that the gold silver ratio will continue to rise. So will it remain weak?

Here is a link to the latest Hoisington Investment Management March report. Their conclusion is that growth and inflation will remain weak, despite the massive money printing and stimulus presently being rolled out by the US government and Federal Reserve. I heartily agree with this analysis. Below is a long-term chart of US GDP:

Source

Growth peaked during the second world war and has been steadily falling since then. Since the war, average growth is falling at .7 of a percent every 10 years. As the US government and Federal Reserve are insistent on bailing out all industries and companies, productivity will remain low. This is because the weak companies will not be eliminated, allowing a re-allocation of the capital from the weak to the strong. Below is the population growth of the US economy for the last decade:

The 2019 growth rate was .6 of 1%. With slow population growth and slow productivity growth, the growth rate of the US economy must remain weak. GDP growth is the product of the change in population growth and the change in productivity growth. If both are weak, GDP must remain weak.

Implications

For investment (not trading) purposes, it is clear that if the gold silver ratio keeps climbing, gold will outperform silver on a long-term basis. If you like precious metals to diversify your portfolio, you should buy gold and not silver. It may well be that the gold silver ratio trades lower in the short term and is a good trade, but it is not the way to go if you are an investor. It is also clear that gold miners will outperform silver miners. I presently have no exposure to any silver mining stocks (although some of my gold miners produce silver as a byproduct). Don’t be fooled into thinking that just because the gold silver ratio has hit a high and is now falling that it will mean revert. We are in a low growth environment for the foreseeable future and the ratio will behave accordingly!

SOURCE: https://seekingalpha.com/article/4338404-gold-silver-ratio-will-keep-on-climbing

Datametrex $DM.ca Provides Update On Health Canada Submission & Welcomes Advisors

Posted by AGORACOM-JC at 7:12 AM on Tuesday, April 21st, 2020
  • Provides additional specifics on the previously announced news release regarding acquiring the rights to import COVID-19 test kits from South Korea
  • An application for approval was made to Health Canada under the Fast-Track program on April 9th, 2020
  • As part of the submission, the Company has submitted a Medical Devices Interim Order Request Form under Interim Order
  • Interim Order (IO) will allow Health Canada to issue expedited review and approval for the sale of these test kits in Canada

TORONTO, April 21, 2020 — Datametrex AI Limited (the “Company” or “Datametrex”) (TSXV: DM, FSE: D4G, OTC: DTMXF ) wishes to provide additional specifics on the previously announced news release regarding acquiring the rights to import COVID-19 test kits from South Korea. An application for approval was made to Health Canada under the Fast-Track program on April 9th, 2020.

As part of the submission, the Company has submitted a Medical Devices Interim Order Request Form under Interim Order Respecting the Importation and Sale of Medical Devices for Use in Relation to COVID-19 pursuant to subsection 30.1(1) of the Food and Drugs Act signed by the Minister of Health on March 18, 2020. This Interim Order (IO) will allow Health Canada to issue expedited review and approval for the sale of these test kits in Canada.

The Company has represented to Health Canada that it will be able to provide a minimum first order of 200,000 units, followed by an additional 100,000 units on a weekly basis. Any purchase of the test kits by the Canadian government is conditional on prior receipt of Health Canada approval. Datametrex is currently working with Dr. Lisa Palleson-Stallan and Dr. Joseph Curtis to assist with obtaining Health Canada approval, and each has agreed to join the Company’s advisory board.

Dr. Joseph Curtis is the Chief Scientific Officer and founder of BioQuant Laboratories (BQL) an independent testing laboratory providing analytical testing services to firms across the U.S. and Canada developing natural product medicines for human and animal health. Dr. Curtis has twenty-five years of experience across and has held various executive positions within public and private sector firms. Working across the public health emergency medical countermeasures continuum, he supported the USA’s blood and tissue preparedness and response programs managed by the American Red Cross. In this capacity, he served as the Director, Biomedical Headquarters Facility Quality Assurance coordinating performance excellence programs across a nation-wide network of manufacturing and testing facilities delivering $2 billion of cellular therapies and transfusion medicine products to over 3,000 hospitals across the US.

Dr. Lisa Palleson-Stallan obtained her Ph.D in International Business with Honours in the U.K. She ran a European Union funded project on technology and Innovation and completed post doctoral work at the World Health Organization (WHO) publishing on Tobacco Cessation. She created her first retail company, Lotuswear, which grew into a 100 employee + company and had the role as presidentand CEO. She became an early adopter in several industries and has continued building value from the ground up. She has built a successful consultancy company that targets the Asian marketplace within the Health space. Dr Palleson-Stallan has been given role and title of Global Health Advisor to assist the Chinese Government with unconditional support and authority to conduct negotiations regarding how to best to combat the spread of Covid-19.

“We are thrilled to be in a position to bring high quality test kits to Canada to help flatten the curve and save lives. We are doing everything we can to provide Health Canada with the required information to move forward. We are looking forward to solving these problems alongside Dr. Palleson-Stallan and Dr. Curtis.”, says Marshall Gunter, CEO of the Company.

Datametrex anticipates that it will have little or no upfront costs associated with importing these test kits. Assuming Health Canada approves the test kits and they are subsequently purchased by the Canadian government, manufacturer will ship the test kits directly to the Canadian government or hospitals, and Datametrex will not be involved in the shipping, warehousing or distribution process.

About Datametrex AI Limited

Datametrex AI Limited is a technology-focused company with exposure to Artificial Intelligence and Machine Learning through its wholly-owned subsidiary, Nexalogy (www.nexalogy.com).
Additional information on Datametrex is available at www.datametrex.com

For further information, please contact:

Marshall Gunter – CEO
Phone: (514) 295-2300
Email: [email protected]

Jeff Stevens – Co-Founder
Phone: (647) 400-8494
Email: [email protected]

Neither the TSX Venture Exchange nor it’s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations, and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.